Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - OtherRevenue - Other
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Depreciation & Amortization (2020 - 2025)

Bolt Biotherapeutics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $6.8 million for Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization rose 2.61% year-over-year to $6.8 million; the TTM value through Jun 2025 reached $6.8 million, up 2.61%, while the annual FY2024 figure was $7.3 million, 26.53% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2025 was $6.8 million at Bolt Biotherapeutics, down from $7.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $7.3 million in Q4 2024 and bottomed at $1.8 million in Q2 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $6.0 million (2023), against an average of $5.1 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 81.19% in 2021 before it grew 2.61% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.2 million in 2021, then soared by 74.39% to $3.9 million in 2022, then surged by 46.92% to $5.8 million in 2023, then increased by 26.53% to $7.3 million in 2024, then decreased by 5.99% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Accumulated Depreciation & Amortization are $6.8 million (Q2 2025), $7.3 million (Q4 2024), and $6.9 million (Q3 2024).